Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 2b Study of Betalutin in Third Line Follicular Lymphoma Patients who are Refractory to Anti-CD20 Therapy

Trial Profile

A Pivotal Phase 2b Study of Betalutin in Third Line Follicular Lymphoma Patients who are Refractory to Anti-CD20 Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 06 Nov 2018 According to a Nordic Nanovector media release, as of 5 November, 51 (of 80-85) sites in 16 (of 20) countries are open for enrolment.
    • 26 Oct 2018 According to a Nordic Nanovector media release, the data from this trial are expected to support market authorisation applications for Betalutin as a new treatment option for third line follicular lymphoma patients (3L FL).
    • 26 Oct 2018 According to a Nordic Nanovector media release, the first clinical site in the United States (in Long Beach, CA) for this pivotal trial has been initiated to enable enrolment of patients.The company anticipate further clinical sites coming on-board in the coming months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top